Starry Sea Acquisition Corp (SSEA)

Starry Sea Acquisition Corp is a Cayman Islands blank check company incorporated in 2024 with the sole purpose of identifying a private business and merging it into a public shell. In September 2025, it announced a binding letter of intent to acquire Forever Young International Limited, a Chinese firm that manages and provides services to medical institutions.

The IPO and timeline

Starry Sea raised $50 million in its initial public offering in August 2025. That might sound modest relative to the mega-SPACs that populated 2020–2021, but it reflects a scaled-back environment: the earliest SPACs were raking in hundreds of millions; by 2024–2025, the appetite for blank cheques had cooled substantially. SSEA also secured $2.47 million in private placement subscriptions, a common structure in which wealthy insiders commit to buy shares at the IPO price to offset some of the dilution that public shareholders will face if the merger happens.

Like all SPACs, Starry Sea had a defined timeline: 15 months from the IPO to complete a business combination. That meant November 2026 was the hard deadline, though SPACs typically ask shareholders for extensions as the clock ticks down.

Forever Young and the Chinese healthcare bet

On September 29, 2025—about a month after its IPO—Starry Sea signed a binding letter of intent with Forever Young International Limited. Forever Young is a Chinese company in the healthcare space, specifically one that provides management and support services to medical institutions. This is distinct from being a hospital operator; Forever Young manages back-office functions, quality control, and administrative support for hospitals and clinics, particularly in China’s primary healthcare system.

The proposed valuation for Forever Young was $750 million to $900 million (pre-money equity value). That figure would be paid to Forever Young’s existing shareholders in the form of stock in the post-merger public company, valued at $10 per share. The deal made sense on the SPAC’s calendar: they had very little time to find a target, and Forever Young needed capital.

Why China and healthcare

The geographic focus on China reflects a long-standing appetite among private equity and SPAC sponsors for Chinese growth stories. Healthcare services is a defensible sector: as incomes rise and populations age, demand for medical services typically grows faster than GDP. Primary healthcare—clinics and smaller hospitals that serve rural and semi-rural China—has been a specific policy focus for the Chinese government.

That said, any SPAC merger involving a Chinese company carries regulatory and geopolitical risks. U.S.-China relations have deteriorated steadily over the decade, and regulators in both countries have become more skeptical of cross-border deals. Chinese healthcare companies have also faced regulatory pressure and accounting scrutiny on U.S. markets.

The letter of intent is not a done deal

A binding letter of intent signals that two companies have committed to try to complete a merger; it is not a completed transaction. Both parties agreed to a 60-day period of mutual exclusivity—neither could shop the deal to other bidders. But exclusivity periods can be extended, due diligence can reveal problems, and either party can walk away if conditions aren’t met.

This is where the distinction between a LOI and a definitive agreement matters. By May 2026, Starry Sea had not yet announced a definitive merger agreement. The LOI was binding in certain respects—exclusivity, confidentiality—but the merger itself required further work and regulatory approval, especially given the China component.

The real risks

SPACs merging with Chinese healthcare companies face several headwinds. First, regulatory: any deal involving a Chinese company may require CFIUS (Committee on Foreign Investment in the United States) review, and such reviews have become more rigorous and more likely to block transactions. Second, execution: Forever Young would need to integrate into a U.S.-listed company, navigate accounting standards (Chinese accounting rules differ from U.S. GAAP), and sustain revenue growth to justify the $750–$900 million valuation. Third, political: any deterioration in U.S.-China relations or additional restrictions on Chinese companies accessing U.S. capital markets could tank the share price after the merger closes.

For public shareholders in the SPAC, the bet is binary: either the deal closes, Forever Young proves to be a good investment, and the shareholders gain; or the deal falls apart or Forever Young underperforms, and shareholders lose. The risk-reward is decidedly asymmetric.